Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Refractory Immune Thrombocytopenia (ITP)
2007-003642-15Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belimumab in immune thrombocytopenia (ITP) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Platelet count after 56 days of therapy with belimumab. Started Jan 2008; status: terminated.
02
Drugs
belimumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2007-003642-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003642-15.